title: Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance.
abstract: Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.
authors.affiliation: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo USP, Ribeirão Preto (SP), Brazil.
authors.forename: Belinda Pinto
authors.initials: BP
authors.lastname: Simões
authors.forename: José Wilson Ramos
authors.initials: JW
authors.lastname: Braga Junior
authors.forename: Maria Aparecida do Carmo
authors.initials: MA
authors.lastname: Rego
authors.forename: Cármino Antônio
authors.initials: CA
authors.lastname: de Souza
keywords: Antineoplastic agents/administration & dosage; Drug monitoring, neoplasm; Drug resistance; Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy; Monitoring; Prognosis; Pyrimidines/therapeutic use; Receptor Protein-Tyrosine Kinases